Malignant Thalamic Neoplasm
There is 1 clinical trial for malignant thalamic neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains malignant thalamic neoplasm as an inclusion criterion, 1 is phase 1 (1 open).
Paxalisib is the most common intervention in malignant thalamic neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.